Gradient Denervation Technologies announced today the company’s pulmonary denervation system has received Breakthrough Device ...

Determine the enteral feeding tube size (e.g., small bore or large bore), insertion site (e.g., nasal or percutaneous ... two hours before and after medication administration if drug absorption ...

The risk of systemic side effects is greater in infants than in adults due to increased percutaneous drug absorption and lower blood volume. The closed eyes technique of eyedrop administration is ...

ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has received CE Mark under the European ...

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...

A near-immediate jump in serum transthyretin after treatment with acoramidis (Attruby) predicted improved survival in ...

Gradient Denervation Technologies announced today that it received FDA breakthrough device designation for its denervation ...

On the heels of a production-tinged executive order earlier this month, the Trump administration is doubling down on efforts ...

Presented at EuroPCR 2025, the results of the 4D-ACS trial show how a shorter antiplatelet regimen after PCI could reduce ...

Sightsavers has declared Abia State’s record of 40,000 in the Safety And Anti-Microbal Resistance Of Mass Drug Administration Of Azithromycin To Children 1-11 months project as successful.

Gradient Denervation Technologies, which is based in Paris, France, announced that the company’s pulmonary artery denervation ...

The indication leverages the same CPT code, insurance coverage, and provider call points as the existing IBS indication, supporting a seamless and capital-efficient go-to-market strategy. Commercial ...